drugset / Trial / NCT00753038

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

NCT00753038

Phase 2 Completed 14 enrolled Oncolytics Biotech
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell carcinoma of the head and neck.

Timeline

Start
2008-08
Primary completion
2011-07
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Pelareorep Other / unclassified 3e+10 unknown Intravenous